NIO Inc. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? NIO Inc. trades at $3.46 (market cap $8.67B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: NIO Inc. is far larger — about 3.8× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| NIO | SLS | |
|---|---|---|
Market Cap | $8.67B | $2.28B |
Volume | 25,622,800 | 3,128,960 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $15.46 |
52-Week Low | $3.37 | $1.39 |
Typical Hold Time | 81 Days | — |
Enterprise Value | $6.57B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 2.01% today and near its 52-week low of $3.38. The stock shows bearish technical signals with negative moving averages, though oscillators are neutral. Fundamentally, revenue grew to $87.49B in 2025 with improving net margin to -17.8%, but the company remains unprofitable with negative ROE of -332.77%. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38B, which could expand NIO's charging network reach.
The outlook remains challenging amid a brutal EV price war in China, though analyst consensus is bullish with a $6.23 price target implying 83% upside. Key risks include persistent losses, high debt, and intense competition. Institutional sentiment is mixed with 50% buy ratings, but the stock's current valuation at 0.51 P/S may attract value investors betting on a long-term turnaround.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →